MDxHealth, Inc. Enters Agreement with University Hospital of Bonn for Use of the Epigenetic MGMT Test in Phase III Brain Cancer Study

IRVINE, Calif., & LIEGE, Belgium--(BUSINESS WIRE)--Regulatory News:

MDxHealth SA (NYSE Euronext:MDXH), a leading molecular diagnostics company in the field of personalized cancer treatment, announced today that it has entered into a companion diagnostic agreement with Prof. Dr. Ulrich Herrlinger of the Division of Clinical Neuro-oncology of the University Hospital of Bonn (Germany) to provide MGMT epigenetic testing.